Feasibility of economic analysis of radiation therapy oncology group (RTOG) 91-11 using medicare data

Andre Konski, Mythreyi Bhargavan, Jean Owen, Rebecca Paulus, Jay Cooper, Arlene A. Forastiere, K. Kian Ang, Deborah Watkins-Bruner

Research output: Contribution to journalArticle

Abstract

Purpose: The specific aim of this analysis was to evaluate the feasibility of performing a cost-effectiveness analysis using Medicare data from patients treated on a randomized Phase III clinical trial. Methods and Materials: Cost data included Medicare Part A and Part B costs from all providers - inpatient, outpatient, skilled nursing facility, home health, hospice, and physicians - and were obtained from the Centers for Medicare & Medicaid Services for patients eligible for Medicare, treated on Radiation Therapy Oncology Group (RTOG) 9111 between 1992 and 1996. The 47-month expected discounted (annual discount rate of 3%) cost for each arm of the trial was calculated in 1996 dollars, with Kaplan-Meier sampling average estimates of survival probabilities for each month and mean monthly costs. Overall and disease-free survival was also discounted 3%/year. The analysis was performed from a payer's perspective. Incremental cost-effectiveness ratios were calculated comparing the chemotherapy arms to the radiation alone arm. Results: Of the 547 patients entered, Medicare cost data and clinical outcomes were available for 66 patients. Reasons for exclusion included no RTOG follow-up, Medicare HMO enrollment, no Medicare claims since trial entry, and trial entry after 1996. Differences existed between groups in tumor characteristics, toxicity, and survival, all which could affect resource utilization. Conclusions: Although we were able to test the methodology of economic analysis alongside a clinical trial using Medicare data, the results may be difficult to translate to the entire trial population because of non-random missing data. Methods to improve Medicare data capture and matching to clinical trial samples are required.

Original languageEnglish (US)
Pages (from-to)436-442
Number of pages7
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume79
Issue number2
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

economic analysis
Radiation Oncology
Medicare
radiation therapy
Radiotherapy
Economics
costs
cost effectiveness
Costs and Cost Analysis
entry
physicians
Cost-Benefit Analysis
Medicare Part A
chemotherapy
exclusion
toxicity
Clinical Trials
health
Skilled Nursing Facilities
resources

Keywords

  • Chemoradiation
  • Cost-effectiveness
  • Laryngeal preservation
  • Medicare data capture

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Feasibility of economic analysis of radiation therapy oncology group (RTOG) 91-11 using medicare data. / Konski, Andre; Bhargavan, Mythreyi; Owen, Jean; Paulus, Rebecca; Cooper, Jay; Forastiere, Arlene A.; Ang, K. Kian; Watkins-Bruner, Deborah.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 79, No. 2, 01.02.2011, p. 436-442.

Research output: Contribution to journalArticle

Konski, Andre ; Bhargavan, Mythreyi ; Owen, Jean ; Paulus, Rebecca ; Cooper, Jay ; Forastiere, Arlene A. ; Ang, K. Kian ; Watkins-Bruner, Deborah. / Feasibility of economic analysis of radiation therapy oncology group (RTOG) 91-11 using medicare data. In: International Journal of Radiation Oncology, Biology, Physics. 2011 ; Vol. 79, No. 2. pp. 436-442.
@article{2758be250fb040318978033e2df84666,
title = "Feasibility of economic analysis of radiation therapy oncology group (RTOG) 91-11 using medicare data",
abstract = "Purpose: The specific aim of this analysis was to evaluate the feasibility of performing a cost-effectiveness analysis using Medicare data from patients treated on a randomized Phase III clinical trial. Methods and Materials: Cost data included Medicare Part A and Part B costs from all providers - inpatient, outpatient, skilled nursing facility, home health, hospice, and physicians - and were obtained from the Centers for Medicare & Medicaid Services for patients eligible for Medicare, treated on Radiation Therapy Oncology Group (RTOG) 9111 between 1992 and 1996. The 47-month expected discounted (annual discount rate of 3{\%}) cost for each arm of the trial was calculated in 1996 dollars, with Kaplan-Meier sampling average estimates of survival probabilities for each month and mean monthly costs. Overall and disease-free survival was also discounted 3{\%}/year. The analysis was performed from a payer's perspective. Incremental cost-effectiveness ratios were calculated comparing the chemotherapy arms to the radiation alone arm. Results: Of the 547 patients entered, Medicare cost data and clinical outcomes were available for 66 patients. Reasons for exclusion included no RTOG follow-up, Medicare HMO enrollment, no Medicare claims since trial entry, and trial entry after 1996. Differences existed between groups in tumor characteristics, toxicity, and survival, all which could affect resource utilization. Conclusions: Although we were able to test the methodology of economic analysis alongside a clinical trial using Medicare data, the results may be difficult to translate to the entire trial population because of non-random missing data. Methods to improve Medicare data capture and matching to clinical trial samples are required.",
keywords = "Chemoradiation, Cost-effectiveness, Laryngeal preservation, Medicare data capture",
author = "Andre Konski and Mythreyi Bhargavan and Jean Owen and Rebecca Paulus and Jay Cooper and Forastiere, {Arlene A.} and Ang, {K. Kian} and Deborah Watkins-Bruner",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.ijrobp.2009.11.059",
language = "English (US)",
volume = "79",
pages = "436--442",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Feasibility of economic analysis of radiation therapy oncology group (RTOG) 91-11 using medicare data

AU - Konski, Andre

AU - Bhargavan, Mythreyi

AU - Owen, Jean

AU - Paulus, Rebecca

AU - Cooper, Jay

AU - Forastiere, Arlene A.

AU - Ang, K. Kian

AU - Watkins-Bruner, Deborah

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Purpose: The specific aim of this analysis was to evaluate the feasibility of performing a cost-effectiveness analysis using Medicare data from patients treated on a randomized Phase III clinical trial. Methods and Materials: Cost data included Medicare Part A and Part B costs from all providers - inpatient, outpatient, skilled nursing facility, home health, hospice, and physicians - and were obtained from the Centers for Medicare & Medicaid Services for patients eligible for Medicare, treated on Radiation Therapy Oncology Group (RTOG) 9111 between 1992 and 1996. The 47-month expected discounted (annual discount rate of 3%) cost for each arm of the trial was calculated in 1996 dollars, with Kaplan-Meier sampling average estimates of survival probabilities for each month and mean monthly costs. Overall and disease-free survival was also discounted 3%/year. The analysis was performed from a payer's perspective. Incremental cost-effectiveness ratios were calculated comparing the chemotherapy arms to the radiation alone arm. Results: Of the 547 patients entered, Medicare cost data and clinical outcomes were available for 66 patients. Reasons for exclusion included no RTOG follow-up, Medicare HMO enrollment, no Medicare claims since trial entry, and trial entry after 1996. Differences existed between groups in tumor characteristics, toxicity, and survival, all which could affect resource utilization. Conclusions: Although we were able to test the methodology of economic analysis alongside a clinical trial using Medicare data, the results may be difficult to translate to the entire trial population because of non-random missing data. Methods to improve Medicare data capture and matching to clinical trial samples are required.

AB - Purpose: The specific aim of this analysis was to evaluate the feasibility of performing a cost-effectiveness analysis using Medicare data from patients treated on a randomized Phase III clinical trial. Methods and Materials: Cost data included Medicare Part A and Part B costs from all providers - inpatient, outpatient, skilled nursing facility, home health, hospice, and physicians - and were obtained from the Centers for Medicare & Medicaid Services for patients eligible for Medicare, treated on Radiation Therapy Oncology Group (RTOG) 9111 between 1992 and 1996. The 47-month expected discounted (annual discount rate of 3%) cost for each arm of the trial was calculated in 1996 dollars, with Kaplan-Meier sampling average estimates of survival probabilities for each month and mean monthly costs. Overall and disease-free survival was also discounted 3%/year. The analysis was performed from a payer's perspective. Incremental cost-effectiveness ratios were calculated comparing the chemotherapy arms to the radiation alone arm. Results: Of the 547 patients entered, Medicare cost data and clinical outcomes were available for 66 patients. Reasons for exclusion included no RTOG follow-up, Medicare HMO enrollment, no Medicare claims since trial entry, and trial entry after 1996. Differences existed between groups in tumor characteristics, toxicity, and survival, all which could affect resource utilization. Conclusions: Although we were able to test the methodology of economic analysis alongside a clinical trial using Medicare data, the results may be difficult to translate to the entire trial population because of non-random missing data. Methods to improve Medicare data capture and matching to clinical trial samples are required.

KW - Chemoradiation

KW - Cost-effectiveness

KW - Laryngeal preservation

KW - Medicare data capture

UR - http://www.scopus.com/inward/record.url?scp=78650806036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650806036&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.11.059

DO - 10.1016/j.ijrobp.2009.11.059

M3 - Article

C2 - 20472371

AN - SCOPUS:78650806036

VL - 79

SP - 436

EP - 442

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -